FDA Grants Approval for Tofacitinib Citrate ANDA219830 by Orient Pharma
The FDA has granted approval for the ANDA219830 application for Tofacitinib Citrate submitted by Orient Pharma.
Asset / Drug
Drug and asset intelligence for Tofacitinib with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
JAK Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.